Dexamethasone Doses and Glycemic Response in Diabetic Cholecystectomy
Effect of Two Different Doses of Intraoperative Dexamethasone on Glycemic Response in Diabetic Patients Undergoing Laparoscopic Cholecystectomy
This randomized double-blind controlled trial aims to compare the effects of two different doses of intraoperative intravenous dexamethasone (4 mg versus 8 mg) versus placebo on perioperative glycemic response in adult patients with diabetes mellitus undergoing laparoscopic cholecystectomy.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Diabetes mellitus is a common comorbidity in patients undergoing surgery. Perioperative hyperglycemia is associated with increased morbidity. Dexamethasone is frequently administered intraoperatively for its antiemetic and anti-inflammatory effects, but it can cause hyperglycemia.
This randomized double-blind trial will allocate adult patients with established diabetes mellitus scheduled for elective laparoscopic cholecystectomy into three groups: Group I (4 mg dexamethasone), Group II (8 mg dexamethasone), and Group III (placebo). Blood glucose will be measured at predefined time points using a glucometer. The primary outcome is the maximum recorded perioperative blood glucose concentration within 24 hours after dexamethasone administration.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Contact
Study Contact
- Name: Arwa M Mostafa, Resident
- Phone Number: 01012885077
- Email: Arwa.18313470@med.aun.edu.eg
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- - Adult patients aged 18 to 60 years.
- Established diabetes mellitus.
- Scheduled for elective laparoscopic cholecystectomy under general anesthesia.
- Written informed consent.
Exclusion Criteria:
- - Patient refusal.
- Morbid obesity, cardiac diseases, hepatic diseases, or renal diseases.
- Endocrine disorders affecting glucose metabolism other than diabetes mellitus.
- Type 1 diabetes mellitus requiring continuous insulin infusion.
- Poorly controlled diabetes mellitus (HbA1c > 9.0%).
- ASA physical status III-IV.
- Recent parenteral or oral steroid therapy.
- Allergy to dexamethasone.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 4 mg Dexamethasone
Patients will receive 4 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds. |
Intravenous 4 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.
Other Names:
|
|
Experimental: 8 mg Dexamethasone
Patients will receive 8 mg of intravenous dexamethasone diluted in 0.9% normal saline to 5 mL, administered intravenously over 30 seconds. |
Intravenous 8 mg dexamethasone diluted in 0.9% normal saline to 5 mL, administered over 30 seconds.
Other Names:
|
|
Placebo Comparator: Placebo
Patients will receive an equivalent volume of 0.9% normal saline intravenously as placebo. |
Equivalent volume of 0.9% normal saline intravenously.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Perioperative Blood Glucose Concentration
Time Frame: At 24 hours
|
Maximum recorded perioperative blood glucose concentration in mg/dL within 24 hours after dexamethasone administration, measured by finger-prick capillary blood glucose using a glucometer. |
At 24 hours
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to Peak Blood Glucose Concentration
Time Frame: At 24 hours
|
Mean time in hours from dexamethasone administration to peak blood glucose concentration. |
At 24 hours
|
|
Proportion of Patients Developing Hyperglycemia
Time Frame: At 24 hours
|
Proportion of patients developing blood glucose > 180 mg/dL. |
At 24 hours
|
|
Proportion of Patients Developing Severe Hyperglycemia
Time Frame: At 24 hours
|
Proportion of patients developing blood glucose > 200 mg/dL or > 250 mg/dL. |
At 24 hours
|
|
Requirement for Rescue Insulin
Time Frame: At 24 hours
|
Proportion of patients requiring rescue insulin during the first 24 postoperative hours. |
At 24 hours
|
|
Incidence of Hypoglycemia
Time Frame: At 24 hours
|
Proportion of patients developing blood glucose < 70 mg/dL. |
At 24 hours
|
|
Postoperative Nausea and Vomiting
Time Frame: At 24 hours
|
Incidence of postoperative nausea and vomiting. |
At 24 hours
|
|
Surgical Site Infection
Time Frame: At 30 days
|
Incidence of surgical site infection. |
At 30 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Ola M Wahba, prof, Anaesthesia , ICU and pain management Department, Assiut University Hospitals
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Endocrine System Diseases
- Metabolic Diseases
- Glucose Metabolism Disorders
- Nutritional and Metabolic Diseases
- Diabetes Mellitus
- Hyperglycemia
- Pharmaceutical Preparations
- Polycyclic Compounds
- Pregnadienes
- Pregnanes
- Steroids
- Fused-Ring Compounds
- Steroids, Fluorinated
- Crystalloid Solutions
- Isotonic Solutions
- Solutions
- Pregnadienetriols
- Dexamethasone
- Saline Solution
Other Study ID Numbers
Other Study ID Numbers
- Dexa-Diabetic-Chole-2026
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.